Medical Record Databases

Pharmacoepidemiology, Fifth Edition

Volumn , Issue , 2012, Pages 224-243

  Ogdie, Alexis ^a   Langan, Sinéad M ^b   Parkinson, John ^c   Dattani, Hassy ^d   Kostev, Karel ^e   Gelfand, Joel M ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b ST THOMAS HOSPITAL   (United Kingdom)

^c MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY   (United Kingdom)

^d Cegedim Strategic Data Medical Research Ltd ^*  (United Kingdom)

^e IQVIA   (United States)

Author keywords

Database; General Practice Research Database; Health Improvement Network; Medical record; Mediplus IMS Disease Analyzer; Population based study; Primary care; United Kingdom; Validation

Indexed keywords

EID: 84867835822     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781119959946.ch15     Document Type: Chapter

References (185)

1. Haynes K, Forde K, Schinnar R, Wong P, Strom B, Lewis J. Cancer incidence in The Health Improvement Network. Pharmacoepidemiol Drug Saf 2009; 18: 730-6.
2. GPRD website. www.gprd.com (accessed August. 2011).
3. Becher H, Kostev K, Schroder-Bernhardi D. Validity and representativeness of the Disease Analyzer patient database for use in pharmacoepidemiological and pharmacoeconomic studies. Int J Clin Pharmacol Ther 2009; 47: 617-26.
4. IMS health website. www.imshealth.com (accessed Aug. 2010).
5. Cegedim. Our data. http://csdmruk.cegedim.com/ our-data/our-data.html (accessed August 2011).
6. IMS Disease Analyzer. http://www.imshealth.de/ sixcms/detail.php?id=1019 (accessed Aug. 2010).
7. deLusignan S, Stephens P, Naeema N, Majeed A. Does feedback improve the quality of computerized medical records in primary care? J American Medical Informatics Assoc 2002; 9: 395-403.
8. Royal College of General Practitioners. www. rcgp.org.uk (accessed Oct. 2010).
9. Heath D. France's health care system. CMAJ 2008; 178: 596.
10. Lopes C. Health care in France: facing hard choices. CMAJ 2007; 177: 1167-9.
11. Rodwin V. The health care system under French national health insurance: lessons for health reform in the United States. Am J Public Health 2003; 93: 31-7.
12. Schlette S, Lisac M, Blum K. Integrated primary care in Germany: the road ahead. Int J Integr Care 2009; 9: e14.
13. Gelfand J, Margolis D, Dattani H. The UK General Practice Research Database. In: Strom B, ed. Pharmacoepidemiology, 4th edn. John Wiley and Sons, 2005, pp. 337-46.
14. THIN Partnership. http://www.thin-uk.com/ partnership.htm (accessed Aug. 2010).
15. Lewis J, Schinnar R, Bilker W, Wang X, Strom B. Validation studies of the health improvement network (THIN) database for pharmacoepidemiology research. Pharmacoepidemiol Drug Saf 2007; 16: 393-401.
16. Dietlein G, Schroder-Bernhardi D. Use of the Mediplus patient database in healthcare research. Int J Clin Pharmacol Ther 2002; 40: 130-3.
17. Herrett E, Thomas S, Schoonen S, Smeeth L, Hall A. Validation and validity of diagnoses in the General Practice Research Database: a systematic review. Br J Clin Pharmacol 2010; 69: 4-14.
18. Wong I, Murray M. The potential of UK clinical databases in enhancing paediatric medication research. Br J Clin Pharmacol 2005; 59: 750-5.
19. Wood L, Martinez C. The General Practice Research Database: role in pharmacovigilance. Drug Safety 2004; 27: 871-81.
20. Wood L, Coulson R. Revitalizing the General Practice Research Database: plans, challenges, and opportunities. Pharmacoepidemiol Drug Saf 2001; 10: 379-83.
21. Lawson D, Sherman V, Hollowell J. The General Practice Research Database. Scientifi c and Ethical Advisory Group. Q J Med 1998; 91: 445-52.
22. Walley T, Mantgani A. The UK General Practice Research Database. Lancet 1997; 350: 1097-9.
23. GarciaRadriguez L, Tolosa L, Ruigomez A,Wallander M. Rheumatoid arthritis in UK primary care: incidence and prior morbidity. Scand J Rheumatol 2009; 38: 173-7.
24. Mulnier H, Seaman H, Raleigh V, Soedamah-Muthu S, Colhoun H, Lawrenson R. Mortality in people with type 2 diabetes in the UK. Diabet Med 2006; 23: 516-21.
25. Delaney J, Daskalopoulou S, Brophy J, Steele R, Opatrny L, Suissa S. Lifestyle variables and the risk of myocardial infarction in the General Practice Research Database. BMC Cardiovasc Disord 2007; 7: 1-8.
26. Szatkowski L, Lewis S, McNeill A, Coleman T. Is smoking status routinely recorded when patients register with a new GP? Fam Pract 2010; 27: 673-5.
27. Langley T, Szatkowski L, Gibson J, Huang Y, McNeill A, Coleman T, et al. Validation of the Health Improvement Network (THIN) primary care database for monitoring prescriptions for smoking cessation medications. Pharmacoepidemiol Drug Saf 2010; 19: 586-90.
28. Farmer R, Lawrenson R, Todd J, Williams T, MacRae K. Oral contraceptives and venous thromboembolic disease. Analysis of the UK General Practice Research Database and the UK MediPlus Database. Hum Reproduct Update 1999; 5: 688-706.
29. Gonzalez-Perez A, GarciaRodriguez L. Prostate cancer risk among men with diabetes mellitus. Cancer Causes Control 2005; 16: 1055-8.
30. Neimann A, Shin D, Wang X, Margolis D, Troxel A, Gelfand J. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol 2006; 55: 829-35.
31. Lewis J, Brensinger C. Agreement between GPRD smoking data: a survey of general practitioners and a population-based survey. Pharmacoepidemiol Drug Saf 2004; 13: 437-41.
32. Cai S, GarciaRadriguez L, Masso-Gonzalez E, Hernandez-Diaz S. Uncomplicated peptic ulcer in the UK: trends from 1997 -2005. Aliment Pharmacol Ther 2009; 30: 1039-48.
33. LoRe V, Haynes K, Forde K, Localio A, Schinnar R, Lewis J. Validity of The Health Improvement Network (THIN) for epidemiologic studies of hepatitis C virus infection. Pharmacoepidemiol Drug Saf 2009; 18: 807-14.
34. Maguire A, Blak B, Thompson M. The importance of defi ning periods of complete mortality reporting for research using automated data from primary care. Pharmacoepidemiol Drug Saf 2009; 18: 76-83.
35. Jordan K, Clarke AM, Symmons DP, Fleming D, Porcheret M, Kadam UT, et al. Measuring disease prevalence: a comparison of musculoskeletal disease using four general practice consultation databases. Br J Gen Pract 2007; 57: 7-14.
36. THIN website. www.thin-uk.com (accessed Aug. 2010).
37. Hall G. Validation of death and suicide recording on the THIN UK primary care database.Pharmacoepidemiol Drug Saf 2009; 18: 120-31.
38. Meal A, Leonardi-Bee J, Smith C, Hubbard R, Bath-Hextall F. Validation of THIN data for non-melanoma skin cancer. Quality in Primary Care 2008; 16: 49-52.
39. Khan N, Harrison S, Rose P. Validity of diagnostic coding within the General Practice Research Database: a systemic review. Br J General Practice 2010; 60: e128-36.
40. Dave S, Peterson I. Creating medical and drug code lists to identify cases in primary care databases. Pharmacoepidemiol Drug Saf 2009; 18: 704-7.
41. Khan N, Perera R, Harper S, Rose P. Adaptation and validation of the Charlson Index for Read/OXMIS coded databases. BMC Fam Pract 2010; 5: 1.
42. Jick H, Jick S, Derby L. Validation of information recorded on general practitioner based computerised data resource in the United Kingdom. BMJ 1991; 302: 766-8.
43. Jick S, Kaye J, Vasilakis-Scaramozza C, Garcia Rodriguez LA, Ruigomez A, Meier CR, et al. Validity of the General Practice Research Database. Pharmacotherapy 2003; 23: 686-9.
44. Charlton R, Cunnington M, Vries Cd, Weil J. Data resources for investigating drug exposure during pregnancy and associated outcomes: the General Practice Research Database (GPRD) as an alternative to pregnancy registries. Drug Safety 2008; 31: 39-51.
45. Devine S, West S, Andrews E, Tennis P, Hammad T, Eaton S. The identifi cation of pregnancies within the general research database. Pharmacoepidemiol Drug Saf 2010; 19: 45-50.
46. Farmer R, Todd J. Pregnancy following oral contraception. 13th Intl Conf Pharmacoepidemiology, Orlando, August 1997. 1997.
47. Martín-Merino E, Ruigómez A, Johansson S, Wallander M, García-Rodriguez L. Study of a cohort of patients newly diagnosed with depression in general practice: prevalence, incidence, comorbidity, and treatment patterns. Prim Care Companion J Clin Psychiatry 2010; 12.
48. Tata L, Lewis S, McKeever T, Smith CJP, Doyle P, Smeeth L, et al. Congenital malformation in children born to women with asthma. Pharmacoepidemiol Drug Saf. 2007; 16(S271).
49. Hardy J, Holford T, Hall G, Bracken M. Strategies for identifying pregnancies in the automated medical records of General Practice Research Database. Pharmacoepidemiol Drug Saf 2004; 13: 749-59.
50. Hardy J, Leaderer B, Holford T, Hall G, Bracken M. Safety of medications prescribed before and during early pregnancy in a cohort of 81,975 mothers from the UK General Practice Research Database. Pharmacoepidemiol Drug Saf 2006; 15: 555-64.
51. McKeever T, Lewis S, Smith C, Collins J, Heatlie H, Frischer M. Siblings, multiple births, and the incidence of allergic disease: a birth cohort study using the West Midlands general practice research database. Thorax 2001; 56: 758-62.
52. Health Act 2009. http://www.dh.gov.uk/en/ Publicationsandstatistics/Legislation/Actsandbills/ DH_093280 (accessed June 2011).
53. Department of Health. Quality and Outcomes Framework. http://www.dh.gov.uk/prod_consum_dh/groups/ dh_digitalassets/@dh/@en/documents/digitalasset/ dh_4088693.pdf(accessed Feb. 2010).
54. Lester H. The UK quality and outcomes framework. BMJ 2008; 337: a2095.
55. Sutton M, Elder R, Guthrie B, Watt G. Record rewards: the effects of targeted quality incentives on the recording of risk factors by primary care providers. Health Economics 2010; 19: 1-13.
56. Wise J. Framework for NHS annual "quality accounts" is launched. BMJ 2009; 339: b3890.
57. Yang Y-X, Hennessy S, Propert K, Hwang W, Sedarat A, Lewis J. Chronic proton pump inhibitor therapy and the risk of colorectal cancer. Gastroenterology 2007; 133: 748-54.
58. Cegedim. Quality assurance. http://csdmruk.cegedim. com/our-data/data-quality.html (accessed June 2011).
59. Crawley D, Ng A, Mainous A, Majeed A, Millett C. Impact of pay for performance on quality of chronic disease management by social class group in England. J R Soc Med 2009; 102: 103-7.
60. McDonald R, Roland M. Pay for performance in primary care in England and California: comparison of unintended consequences. Ann Fam Med 2009; 7: 121-7.
61. Doran T, Fullwood C, Gravelle H, Reeves D, Kontopantelis E, Hiroeh U, et al. Pay-for-performance programs in family practices in the United Kingdom. N Engl J Med 2006; 355: 375-84.
62. Campbell S, Reeves D, Kontopantelis E, Middleton E, Siddald B, Roland M. Quality of primary care in England with the introduction of pay for performance. N Engl J Med 2007; 357: 181-90.
63. Szklo M. Population-based cohort studies. Epidemiologic Reviews 1998; 20: 81-90.
64. Rothman K, Greenland S. Modern Epidemiology. Philadelphia: Lippincott-Raven, 1988, pp. 93-115.
65. Hollowell J. The General Practice Research Database: quality of morbidity data. Popul Trends 1997; 87: 36-40.
66. Fombonne E, Heavey L, Smeeth L, Rodrigues L, Cook C, Smith P. Validation of the diagnosis of autism in general practitioner records. BMC Public Health 2004; 4: 5.
67. Hammad T, McAdams M, Feight A, Iyasu S, Dal Pan G. Determining the predictive value of Read/OXMIS codes to identify incident acute myocardial infarction in the General Practice Research Database. Pharmacoepidemiol Drug Saf 2008; 17: 1197-201.
68. Ruigomez A, Johannson S, Wallander M, Rodriguez L. Incidence of chronic atrial fi brillation in general practice and its treatment pattern. J Clin Epidemiol 2002; 55: 358-63.
69. Jick H. Calcium-channel blockers and risk of cancer. Lancet 1997; 349: 1699-700.
70. Derby L, Maier W. Risk of cataract among users of intranasal corticosteroids. J Allergy Clin Immunol 2000; 105: 912-16.
71. Soriano J, Maier W, Visick G, Pride N. Validation of general practitioner-diagnosed COPD in the UK General Practice Research Database. Eur J Epidemiol 2001; 17: 1075-80.
72. Lewis J, Brensinger C, Bilker W, Strom B. Validity and completeness of the General Practice Research Database for studies of inflammatory bowel disease. Pharmacoepidemiol Drug Saf 2002; 11: 211-18.
73. Lewis J, Brensinger C, Bilker W, Deren J, Vaughn D, Strom B. Inflammatory bowel disease is not associated with an increased risk of lymphoma. Gastroenterology 2001; 121: 1080-7.
74. Van Staa T, Selby P, Leufkens H, Lyles K, Sprafka J, Cooper C. Incidence and natural history of Paget 's disease of bone in England and Wales. J Bone Min Res 2002; 17: 465-71.
75. Thomas S, Edwards C, Smeeth L, Cooper C, Hall A. How accurate are diagnoses for rheumatoid arthritis and juvenile idiopathic arthritis in the general practice research database? Arthritis Rheum 2008; 59: 1314-21.
76. Margolis D, Bilker W, Knauss J, Baumgarten M, Strom B. The incidence and prevalence of pressure ulcers among elderly patients in general medical practice. Ann Epidemiol 2002; 12: 321-5.
77. Gelfand J, Weinstein R, Porter S, Neimann A, Berlin J, Margolis D. Prevalence and treatment of psoriasis in the United Kingdom: a population-based study. Arch Dermatol 2005; 141: 1537-41.
78. Seminara NM, Abuabara K, Shin DB, Langan SM, Kimmel SE, Margolis D, et al. Validity of The Health Improvement Network (THIN) for the study of psoriasis. Br J Dermatol 2011; 164: 602-9.
79. Nazareth I, King M, Haines A, Rangel L, Myers S. Accuracy of diagnosis of psychosis on general practice computer system. BMJ 1993; 307: 32-4.
80. Jick S, Dean A, Jick H. Antidepressants and suicide. BMJ 1995; 310: 215-18.
81. Lawrenson R, Todd J, Leydon G, Williams T, Farmer R. Validation of the diagnosis of venous thromboembolism in general practice database studies. Pharmacoepidemiol Drug Saf 2000; 49: 591-6.
82. Arellano F, Conde E, Wenworth C, Schlienger R, Fernandez-Vidaurre C, Arana A. Validation of cases of lymphoma in THIN. Pharmacoepidrmiol Drug Saf 2008; 17: S87-8.
83. Todd J, Lawrenson R, Farmer R, Williams T, Leydon G. Venous thromboembolic disease and combined oral contraceptives: A re-analysis of the MediPlus database. Human Reproduction 1999; 14: 1500-5.
84. Arellano F, Arana A, Wentworth C, Fernandez-Vidaurre C, Schlienger R, Conde E. Lymphoma among patients with atopic dermatitis and/or treated with topical immunosuppressants in the United Kingdom. J Allergy Clin Immunol 2009; 123: 1111-16.
85. Bourke A, Dattani H, Robinson M. Feasibility study and methodology to create a quality evaluated database of primary care data. Informatics in Primary Care 2004; 12: 171-7.
86. VanStaa T, Abenhaim L, Cooper C, Zhang B, Leufkens H. The use of a large pharmacoepidemiological database to study exposure to oral corticosteroids and risk of fractures: validation of study population and results. Pharmacoepidemiol Drug Saf 2000; 9: 359-66.
87. Lewis J, Bilker W, Weinstein R, Strom B. The relationship between time since registration and measured incidence rates in the General Practice Research Database. Pharmacoepidemiol Drug Saf 2005; 14: 443-51.
88. Linsell L, Dawson J, Zondervan K, Randall T, Rose P, Carr A, et al. Prospective study of elderly people comparing treatments following fi rst primary care consultation for a symptomatic hip or knee. Family Practice 2005; 22: 118-25.
89. Bath-Hextall F, Leonardi-Bee J, Smith C, Meal A, Hubbard R. Trends in incidence of skin basal cell carcinoma: Additional evidence from a UK primary care database study. Int J Cancer 2007; 121: 2105-8.
90. Fischer L, Schlienger R, Matter C, Jick H, Meier C. Effect of rheumatoid arthritis or systemic lupus erythematosus on the risk of fi rst-time acute myocardial infarction. Am J Cardiol 2004; 93: 198-200.
91. Gupta D, Hansell A, Nichols T, Duong T, Ayres J, Strachan D. Epidemiology of pneumothorax in England. Thorax 2000; 55: 666-71.
92. Humes D, Solaymani-Dodaran M, Fleming K, Simpson J, Spiller R, West J. A population-based study of perforated diverticular disease incidence and associated mortality. Gastroenterology 2009; 136: 1198-205.
93. Punekar Y, Sheikh A. Establishing the incidence and prevalence of clinician-diagnosed allergic conditions in children and adolescents using routinely collected data from general practices. Clin Exp Allergy 2009; 39: 1209-16.
94. Souverein P, Webb D, Petri H, Weil J, Staa TV, Egberts T. Incidence of fractures among epilepsy patients: a population-based retrospective cohort study in the General Practice Research Database. Epilepsia 2005; 46: 304-10.
95. Somers E, Thomas S, Smeeth L, Schoonen W, Hall A. Incidence of systemic lupus erythematosus in the United Kingdom; 1990 -1999. Arthritis Rheum 2007; 57: 612-18.
96. Linsell L, Dawson J, Zondervan K, Rose, P, Randall T, Fitzpatrick R, et al. Prevalence and incidence of adults consulting for shoulder conditions in UK primary care; patters of diagnosis and referral. Rheumatology 2006; 45: 215-21.
97. Johansson S, Wallander M, Ruigomez A, Garcia-Rodriguez L. Incidence of newly diagnosed heart failure in UK general practice. Eur J Heart Fail 2001; 3: 225-31.
98. Langan S, Smeeth L, Hubbard R, Fleming K, Smith C, West J. Bullous pemphigoid and pemphigus vulgaris-incidence and mortality in the UK: population based cohort study. BMJ 2008; 337: a180.
99. Ruigómez A, Wallander M, Johansson S, García-Rodríguez L. One-year follow-up of newly diag nosed irritable bowel syndrome patients. Aliment Pharmacol Ther 1999; 13: 1097-102.
100. Kaplan G, Hubbard J, Korzenik J, Sands BE, Panaccione R, Ghosh S, et al. The inflammatory bowel diseases and ambient air pollution: a novel association. Am J Gastroenterol 2010; 105: 2412-9.
101. Solaymani-Dodaran M, Aithal G, Card T, West J. Risk of cardiovascular and cerebrovascular events in primary biliary cirrhosis: a population-based cohort. Am J Gastroenterol 2008; 103: 2784-8.
102. Clayton T, Thompson M, Meade T. Recent respiratory infection and risk of cardiovascular disease: case-control study through a general practice database. Eur Heart J 2008; 29: 96-103.
103. Gelfand J, Neimann A, Shin D, Wang X, Margolis D, Troxel A. Risk of myocardial infarction in patients with psoriasis. JAMA 2006; 296: 1735-42.
104. Pujades-Rodriguez M, Smith C, Hubbard R. Inhaled corticosteroids and the risk of fracture in chronic obstructive pulmonary disease. Q J Med 2007; 100: 509-17.
105. Breart G, Cooper C, Meyer O, Speirs C, Deltour N, Reginster J. Osteoporosis and venous thromboembolism: a retrospective cohort study in the UK General Practice Research Database. Osteoporos Int 2010; 21: 1181-7.
106. Hernán M, Jick S, Logroscino G, Olek M, Ascherio A, Jick H. Cigarette smoking and the progression of multiple sclerosis. Brain 2005; 128: 1461-5.
107. Lewis N, Logan R, Hubbard R, West J. No increase in risk of fracture, malignancy or mortality in dermatitis herpetiformis: a cohort study. Aliment Pharmacol Ther 2008; 27: 1140-7.
108. VanStaa T, Geusens P, Pols H, Laet CD, Leufkens H, Cooper C. A simple score for estimating the long-term risk of fracture in patients using oral glucocorticoids. Q J Med 2005; 98: 191-8.
109. Huerta C, Zhao S, GarciaRodriguez L. Risk of acute liver injury in patients with diabetes. Pharmacotherapy 2002; 22: 1091-6.
110. Davies A, Smeeth L, Grundy E. Contribution of changes in incidence and mortality to trends in the prevalence of coronary heart disease in the UK: 1996-2005. Eur Heart J 2007; 28: 2142-7.
111. Davey G, Sedgwick P, Maier W, Visick G, Strachan D, Anderson H. Association between migraine and asthma: matched case-control study. Br J Gen Pract 2002; 52: 723-7.
112. Meier C, Krahenbuhl S, Schlienger R, Jick H. Association between body mass index and liver disorders: an epidemiological study. J Hepatol 2002; 37: 741-7.
113. Zondervan K, Yudkin P, Vessey M, Dawes M, Barlow D, Kennedy S. Patterns of diagnosis and referral in women consulting for chronic pelvic pain in UK primary care Br J Obstet Gynaecol 1999; 106: 1156-61.
114. Zondervan K, Yudkin P, Vessey M, Dawes M, Barlow D, Kennedy S. Prevalence and incidence of chronic pelvic pain in primary care: evidence from a national general practice database. Br J Obstet Gynaecol 1999; 106: 1149-55.
115. Blumentals W, Brown R, Gomez-Caminero A. Antihypertensive treatment and erectile dysfunction in a cohort of type II diabetes patients. Int J Impot Res 2003; 15: 314-17.
116. Kornegay C, Vasilakis-Scaramozza C, Jick H. Incident diabetes associated with antipsychotic use in the United Kingdom general practice research database. J Clin Psychiatry 2002; 63: 758-62.
117. VanStaa T, Abenhaim L, Monette J. Rates of hypoglycemia in users of sulfonylureas. J Clin Epidemiol 1997; 50: 735-41.
118. Langman M, Eichler E, Mavros P, Watson D, Kong S. Initiation of antihypertensive therapy among new users of cyclooxygenase-2-selective and nonselective NSAIDs. Int J Clin Pharmacol Therap 2004; 42: 260-6.
119. Mochenhaupt M, Messenheimer J, Tennis P, Schlingmann J. Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis in new users of antiepileptics. Neurology 2005; 64: 1134-8.
120. Molokhia M, McKeigue P, Curcin V, Majeed A. Statin induced myopathy and myalgia: time trend analysis and comparison of risk associated with statin class from 1991 -2006. PLoS ONE 2008; 3: e2522.
121. Zhang H, Carcia-Rodriguez L, Hernandez-Diaz S. Antibiotic use and the risk of lung cancer. Cancer Epidemiol 2008; 17: 1308-15.
122. Becker C, Jick S, Meier C. Use of statins and the risk of Parkinson 's disease: a retrospective case-control study in the UK. Drug Safety 2008; 31: 399-407.
123. Castellsague J, García-Rodríguez L, Duque A, Pérez S. Risk of serious skin disorders among users of oral antifungals: a population-based study. BMC Dermatol 2002; 2: 14.
124. Meier C, Derby L, Jick S, Vasilakis C, Jick H. Antibiotics and risk of subsequent fi rst-time acute myocardial infarction. JAMA 1999; 281: 427-31.
125. Meier C, Wilcock K, Jick S. The risk of severe depression, psychosis or panic attacks with prophylactic antimalarials. Drug Safety 2004; 27: 203-13.
126. Edwards C, Cooper C, Fisher D, Field M, VanStaa T, Arden N. The importance of the disease process and disease-modifying antirheumatic drug treatment in the development of septic arthritis in patients with rheumatoid arthritis. Arthritis Rheum 2007; 57: 1151-7.
127. Bulugahapitiya U, Siyambalapitiya S, Sithole J, Fernando D, Idris I. Age threshold for vascular prophylaxis by aspirin in patients without diabetes. Heart 2008; 94: 1429-32.
128. Gore M, Sadosky A, Leslie D, Sheehan A. Medication for treating neuropathic pain in patients with diabetes: a study using the UK and Germany Mediplus databases. Pain Practice 2008; 8: 253-62.
129. Simons W, Vinod H, Gerber R, Bolinder B. Does rapid transition to insulin therapy in subjects with newly diagnosed type 2 diabetes mellitus benefi t glycaemic control and diabetes-related complications? A German population-based study. Exp Clin Endocrinol Diab 2006; 114: 520-6.
130. Smeeth L, Douglas I, Hall A, Hubbard R, Evans S. Effect of statins on a wide range of health outcomes: a cohort study validated by comparison with randomized trials. Br J Clin Pharmacol 2008; 67: 99-109.
131. Thomas M,Williams A. Are outcomes the same with all dry powder inhalers? Int J Clin Pract 2005; 59 (Suppl 149): 33-5.
132. Zhang Q, Thomas M, Wisniewski T, Kocevar V, Price D. Treatment and outcomes in patients with asthma and allergic rhinitis in the UK. Allergy Immunol 2007; 142: 318-28.
133. McCarthy S, Cranswick N, Potts L, Taylor E, Wong I. Mortality associated with attention-defi cit hyperactivity disorder (ADHD) drug treatment: a retrospective cohort study of children, adolescents and young adults using the general practice research database. Drug Safety 2009; 32: 1089-96.
134. Hubbard R, Lewis S, West J, Smith C, Godfrey C, Smeeth L, et al. Bupropion and the risk of sudden death: a self-controlled case-series analysis using The Health Improvement Network. Thorax 2005; 60: 848-50.
135. Gaus W, Westendorf J, Diebow R, Kieser K. Identifi cation of adverse drug reactions by evaluation of a prescription database, demonstrated for "risk of bleeding ". Methods Inf Med 2005; 44: 697-703.
136. Langman M, Kong S, Zhang Q, Kahler K, Finch E. Safety and patient tolerance of standard and slow-release formulations of NSAIDs. Pharmacoepidemiol Drug Saf 2003; 12: 61-6.
137. Margolis D, Hoffstad O, Strom B. Association between serious ischemic cardiac outcomes and medications used to treat diabetes. Pharmacoepidemiol Drug Saf 2008; 17: 753-9.
138. Tata L, Fortune P, Hubbard R, Smeeth L, Hawkey CJ, Smith CJ, et al. Does concurrent prescription of selective serotonin reuptake inhibitors and non-steroidal anti-inflammatory drugs substantially increase the risk of upper gastrointestinal bleeding? Aliment Pharmacol Ther 2005; 22: 175-81.
139. Wood S, Jick H, Sauve R. The risk of stillbirth in pregnancies before and after the onset of diabetes. Diabet Med 2003; 20: 703-7.
140. Gonzalez M, Garcia-Rodriguez L. Proton pump inhibitors reduce the long-term risk of recurrent upper gastrointestinal bleeding: an observational study. Aliment Pharmacol Ther 2008; 25: 629-37.
141. Schembri S Morant S, Winter JH, MacDonald T. Influenza and pneumococcal vaccination protect against all cause mortality in patients with COPD. Thorx. 2009; 64: 567-72.
142. Bremner S, Carey I, DeWilde S, Richards N, Maier W, Hilton S. Vaccinations, infections and antibacterials in the fi rst grass pollen season of life and risk of later hayfever. Clin Exp Allergy 2007; 37: 512-17.
143. Belsey J. Non-steroidal anti-inflammatory induced upper gastrointestinal event rates in patients awaiting joint replacement in the United Kingdom. An epidemiologically-based burden of disease model. Curr Med Res Opin 2003; 19: 306-12.
144. Rodríguez LG, Varas C, Patrono C. Differential effects of aspirin and non-aspirin nonsteroidal antiinflammatory drugs in the primary prevention of myocardial infarction in postmenopausal women. Epidemiology 2000; 11: 382-7.
145. Arellano F, Wentworth C, May C, Verma A, Cid J. Patterns of discontinuation, Dose modifi cation and switching among users of prescription non-steroidal anti-inflammatory drugs (NSAID) including cyclo-oxygenase 2 inhibitors (COX-2) in the UK population. Pharmacoepidemiol Drug Saf 2005; 14 (Suppl 2): S1.
146. Gopal M, Haynes K, Bellamy S, Arya L. Discontinuation rates of anticholinergic medications used for the treatment of lower urinary tract symptoms. Obstet Gynecol 2008; 112: 1311-8.
147. Hasford J, Schroder-Bernhardi D, Rottenkolber M, Kostev K, Dietlein G. Persistence with antihypertensive treatments: results of a 3-year follow up cohort study. Eur J Clin Pharmacol 2007; 63: 1055-61.
148. Suarez A, Staffa J, Fletcher P, Jones J. Reason for discontinuation of newly prescribed antihypertensive medications: methods of a pilot study using computerized patient records. Pharmacoepidemiol Drug Saf 2000; 9: 405-16.
149. Cramer J, Gold D, Silverman S, Lewiecki E. A systematic review of persistence and compliance with bisphosphonates for osteoporosis. Osteoporos Int 2007; 18: 1023-31.
150. VanStaa T, Geusens P, Leufkens H, Cooper C. Persistence to bisphosphonate treatment in actual clinical practice. Bone 2005; 36 (S2): S412.
151. Lafuma A, Berdeaux G. Costs and persistence of carbonic anhydrase inhibitor versus alpha-2 agonists, associated with beta-blockers, in glaucoma and ocular hypertension: an analysis of the UK-GPRD database. Curr Med Res Opin 2008; 24: 1519-27.
152. Schroder-Bernhardi D, Dietlein G. Compliance with prescription recommendations by physicians in practices. Int J Clin Pharm Therap Nov 2001; 39: 477-9.
153. Mikuls T, Farrar J, Bilker W, Fernandes S, Saag K. Suboptimal physician adherence to quality indicators for the management of gout and asymptomatic hyperuricaemia: results from the UK General Practice Research Database (GPRD). Rheumatology 2005; 44: 1038-42.
154. Thompson P, Spyridis N, Sharland M, Gilbert RE, Saxena S, Long PF, et al. Changes in clinical indications for community antibiotic prescribing for children in the UK from 1996 to 2006: will the new NICE prescribing guidance on upper respiratory tract infections just be ignored? Arch Dis Child 2009; 94: 337-40.
155. Murray M, Thompson M, Santosh P, Wong I. Effects of the committee on safety of medicines advice on antidepressant prescribing to children and adolescents in the UK. Drug Safety 2005; 28: 1151-7.
156. Munson J, Kreider M, Chen Z, Christie J, Kimmel S. Factors associated with the use of corticosteroids in the initial management of idiopathic pulmonary fi brosis. Pharmacoepidemiol Drug Saf 2010; 19: 756-62.
157. Arellano F, Yood M, Wentworth C, Oliveria SA, Rivero E, Verma A, et al. Use of cyclo-oxygenase 2 inhibitors (COX-2) and prescription non-steroidal anti-inflammatory drugs (NSAIDS) in UK and USA populations. Implications for COX-2 cardiovascular profi le. Pharmacoepidemiol Drug Saf 2006; 15: 861-72.
158. Boyc K, Yurgin N. Trends in the prescription of antidiabetic medications in France: evidence from primary care physicians. Adv Ther 2007; 24: 803-14.
159. Sittle R, Nuijten M, Nautrup B. Patterns of dosage changes with transdermal buprenorphine and transdermal fentanyl for the treatment of noncancer and cancer pain: a retrospective data analysis in Germany. Clin Therap 2006; 28: 1144-54.
160. Dietlein G, Schroder-Bernhardi D. Doctors' prescription behaviour regarding dosage recommendations for preparations of kava extracts. Pharmacoepidemiol Drug Saf 2003; 12: 417-21.
161. Schroder-Bernhardi D, Dietlein G. Lipid-lowering therapy: do hospitals influence the prescribing behavior of general practitioners? Int J Clin Pharm Therap 2002; 40: 317-21.
162. MacDonald T, Morant S. Prevalence and treatment of isolated and concurrent hypertension and hypercholesterolaemia in the United Kingdom. Br J Clin Pharmacol 2008; 65: 775-86.
163. Turner S, Thomas M, Ziegenweidt JV, Price D. Prescribing trends in asthma: a longitudinal observational study. Arch Dis Child 2009; 94: 16-22.
164. Edwards C, Arden N, Fisher D, Saperia J, Reading I, VanStaa T. The changing use of disease-modifying anti-rheumatic drugs in individuals with rheumatoid arthritis from the United Kingdom General Practice Research Database. Rheumatology 2005; 44: 1394-8.
165. Suh D, Hunsche E, Shin H, Mavros P. Co-prescribing of proton pump inhibitors among chronic users of NSAIDs in the UK. Rheumatology 2008; 47: 458-63.
166. Krobot K, Miller W, Kaufman J, Christensen D, Preisser J, Ibrahim M. Quantifying delay in access to new medical treatment: an application of risk advancement period methodology. Epidemiology 2004; 15: 202-7.
167. Belsey J, Pittard J, Rao S, Urdahl H, Jameson K, Dixon T. Self blood glucose monitoring in type 2 diabetes: a fi nancial impact analysis based on UK primary care. Int J Clin Pract 2009; 63: 439-48.
168. VanStaa T, Geusens P, Leufkens H, Cooper C. An individualised model of cost-effectiveness of bisphosphonates in elderly women. Bone 2005; 36 (S2): S138.
169. Lafuma A, Berdeaux G. Costs and effectiveness of travoprost versus a dorzolamide + timolol fi xed combination in fi rst-line treatment of glaucoma: analysis conducted on the United Kingdom General Practitioner Research Database. Curr Med Res Opin 2007; 23: 3009-16.
170. Varney S, Guest J. Relative cost effectiveness of Depo-Provera, Implanon, and Mirena in reversible long-term hormonal contraception in the UK. Pharmacoeconomics 2004; 22: 1141-51.
171. Plumb J, Edwards S. Cost effectiveness analysis of proton pump inhibitors compared to omeprazole in the healing of reflux oesophagitis. J Med Econ 2002; 5: 25-38.
172. Guest J, Hart W, Cookson R. Cost analysis of palliative care for terminally ill cancer patients in the UK after switching from weak to strong opioids. Palliative Care Advisory Committee. Pharmacoeconomics 1998; 14: 285-97.
173. Poole C, Lebmeier M, Ara R, Rafi a R, Currie C. Estimation of health care costs as a function of disease severity in people with psoriatic arthritis in the UK. Rheumatology 2010; 49: 1949-56.
174. Guest J, Clegga J, Helter M. Cost-effectiveness of macrogol 4000 compared to lactulose in the treatment of chronic functional constipation in the UK. Curr Med Res Opin 2008; 24: 1841-52.
175. Krobot K, Kaufman J, Christersen D, Preisser J, Miller W, Ibrahim M. Accessing a new medication in Germany: A novel approach to assess a health insurance-related barrier. Ann Epidemiol 2005; 15: 756-61.
176. Krobot K, Miller W, Kaufman J, Christ D. The disparity in access to new medication by type of health insurance: lessons from Germany. Medical Care 2004; 42: 487-91.
177. Berger A, Sadosky A, Dukes E, Martin S, Edelsberg J, Oster G. Characteristics and patterns of healthcare utilization of patients with fi bromyalgia in general practitioner settings in Germany. Curr Med Res Opin 2008; 24: 2489-99.
178. Poole C, Tetlow T, McEwan P, Holmes P, Currie C. The prescription cost of managing people with type 1 and type 2 diabetes following initiation of treatment with either insulin glargine or insulin detemir in routine general practice in the UK: a retrospective database analysis. Curr Med Res Opin 2007; 8: 41-8.
179. Rathmann W, Haastert B, Giani G. Drug prescriptions and costs in the treatment of diabetic polyneuropathy. Ditsch Med Wschr 1999; 124: 681-6.
180. Icks A, Haastert B, Giani G, Rathmann W. Incremental prescription and drug costs during the years preceding diabetes diagnosis in primary care practices in Germany. Exp Clin Endocrinol Diabetes 2006; 114: 348-55.
181. Gulliford M, Latinovic R, Charlton J. Diabetes diagnosis, resource utilization, and health outcomes. Am J Manag Care 2008; 14: 32-8.
182. Blak B, Mullins C, Shaya F, Simoni-Wastila L, Cooke C, Weir M. Prescribing trends and drug budget impact of the ARBs in the UK. Value Health 2008; 12: 302-8.
183. Hughes D, McGuire A. The direct costs to the NHS of discontinuing and switching prescriptions for hypertension. J Human Hypertension Aug 1998; 12: 533-7.
184. Tate A, Nicholson A, Cassell J. Are GPs under-investigating older patients presenting with symptoms of ovarian cancer? Observational study using General Practice Research Database. Br J Cancer 2010; 102: 947-51.
185. Joseph C, Goddard N, Gelb D. Influenza vaccine uptake and distribution in England and Wales using data from the General Practice Research Database, 1989/90-2003/04. J Public Health Dec 2005; 27: 371-7.